Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

KERNEIS

Showing results (181-190 of 209) with videos related to

Pageof 21
Sort By:
American Heart Journal|June 5, 2020
Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trialPaul Guedeney, Holger Thiele, Mathieu Kerneis, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 11, 2018
Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trialEnrico Fabris, Arnoud Van't Hof, Christian W Hamm, et al.
American Heart Journal|December 24, 2018
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarctionC Michael Gibson, Mathieu Kerneis, Megan K Yee, et al.
JACC. Cardiovascular Interventions|June 6, 2024
Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary SyndromeStéphane Manzo-Silberman, Paul Guedeney, Guillaume Cayla, et al.
Clinical Cardiology|February 17, 2016
Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-GenerationJean-Philippe Collet, Johanne Silvain, Mathieu Kerneis, et al.
Lancet (London, England)|July 20, 2014
Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trialJean-Philippe Collet, Johanne Silvain, Olivier Barthélémy, et al.
European Heart Journal|September 3, 2015
EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT)Michel Komajda, Franz Weidinger, Mathieu Kerneis, et al.
European Heart Journal|May 18, 2022
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trialJean Philippe Collet, Eric Van Belle, Holger Thiele, et al.
European Heart Journal. Acute Cardiovascular Care|August 26, 2017
Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC TrialEnrico Fabris, Arnoud van 't Hof, Christian W Hamm, et al.
The New England Journal of Medicine|November 6, 2012
Bedside monitoring to adjust antiplatelet therapy for coronary stentingJean-Philippe Collet, Thomas Cuisset, Grégoire Rangé, et al.
Pageof 21

Showing results (181-190 of 209) with videos related to

Sort By:
Pageof 21
American Heart Journal|June 5, 2020
Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trialPaul Guedeney, Holger Thiele, Mathieu Kerneis, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 11, 2018
Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trialEnrico Fabris, Arnoud Van't Hof, Christian W Hamm, et al.
American Heart Journal|December 24, 2018
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarctionC Michael Gibson, Mathieu Kerneis, Megan K Yee, et al.
JACC. Cardiovascular Interventions|June 6, 2024
Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary SyndromeStéphane Manzo-Silberman, Paul Guedeney, Guillaume Cayla, et al.
Clinical Cardiology|February 17, 2016
Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-GenerationJean-Philippe Collet, Johanne Silvain, Mathieu Kerneis, et al.
Lancet (London, England)|July 20, 2014
Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trialJean-Philippe Collet, Johanne Silvain, Olivier Barthélémy, et al.
European Heart Journal|September 3, 2015
EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT)Michel Komajda, Franz Weidinger, Mathieu Kerneis, et al.
European Heart Journal|May 18, 2022
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trialJean Philippe Collet, Eric Van Belle, Holger Thiele, et al.
European Heart Journal. Acute Cardiovascular Care|August 26, 2017
Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC TrialEnrico Fabris, Arnoud van 't Hof, Christian W Hamm, et al.
The New England Journal of Medicine|November 6, 2012
Bedside monitoring to adjust antiplatelet therapy for coronary stentingJean-Philippe Collet, Thomas Cuisset, Grégoire Rangé, et al.
Pageof 21